Translate Bio, Inc.

( )
TBIO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 0.45%436.000.0%$6102.94m
BNTXBioNTech SE 0.63%343.490.0%$1152.67m
NVAXNovavax, Inc. -0.02%230.2579.4%$904.95m
SNSSSunesis Pharmaceuticals, Inc. 0.00%8.510.7%$594.88m
AMGNAmgen, Inc. 0.74%216.951.4%$551.53m
GILDGilead Sciences, Inc. -0.06%71.691.0%$450.10m
REGNRegeneron Pharmaceuticals, Inc. -0.26%645.242.7%$443.57m
TECHBio-Techne Corp. 0.00%530.204.5%$363.13m
ILMNIllumina, Inc. 0.35%436.303.5%$361.07m
BIIBBiogen, Inc. -2.85%287.131.7%$292.09m
VRTXVertex Pharmaceuticals, Inc. 0.96%187.591.9%$246.73m
ISEEIVERIC bio, Inc. -1.48%16.010.0%$188.06m
LIFEaTyr Pharma, Inc. -2.75%11.682.1%$170.31m
BGNEBeiGene Ltd. 0.00%388.511.3%$155.67m
EXASEXACT Sciences Corp. 0.00%105.5818.1%$132.87m

Company Profile

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.